[Skip to Content]
[Skip to Content Landing]
July 9, 1997

Estrogen Trial for Patients with Endometrial Cancer

JAMA. 1997;278(2):104. doi:10.1001/jama.1997.03550020036016

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


TO RESOLVE the question of whether estrogen replacement therapy (ERT) is safe even for women who have had earlystage endometrial cancer, a multicenter randomized trial will begin enrolling patients this summer.

The Gynecologic Oncology Group of the American College of Obstetricians and Gynecologists (ACOG), Washington, DC, hopes to enroll at least 2000 women in the National Cancer Institute (NCI)—sponsored ERT Study, said principal investigator Richard Barakat, MD. Speaking at ACOG's 45th annual meeting in Las Vegas, Nev, Barakat, who is an attending physician at Memorial Sloan-Kettering Cancer Center, New York, NY, called on all ACOG members and other physicians to help recruit for this study.

In the past, ERT has not been recommended for postmenopausal women with a history of uterine cancer because of concern that the estrogen might increase the risk of recurrence, said Robert C. Park, MD, chair of the Gynecologic Oncology Group. "We now have no evidence